Szeged

• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla … Recruiting
  2023-507746-83-00 5 2024-11-27 Generalized Myasthenia Gravis
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting
  2023-503545-67-00 5 2024-04-30 Tourette's Disorder
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting
  2022-500718-24-00 5 2023-06-09 IgG4-Related Disease
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting
  2022-500367-12-00 5 2022-11-30 Dermatomyositis
• OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting
  2023-509694-22-00 5 2022-01-26 Ulcerative Colitis (UC)
• A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting
  2023-505638-82-00 5 2022-01-12 Atypical Hemolytic Uremic Syndrome (aHUS)
• AMAZE 2: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and type 2 diabetes lose wei … Recruiting
  2024-520441-23-00 5 2026-05-13 Overweight or obesity, and type 2 diabetes
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting
  2025-523938-10-00 5 2026-05-05 Diabetic Macular Edema (DME)
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting
  2025-523260-20-00 4 2026-04-28 type 2 diabetes
• Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting
  2024-513174-22-00 4 2026-04-14 Atrophic Age-related Macular Degeneration (AMD)
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting
  2025-522231-34-00 5 2026-03-31 Diabetic Macular Edema

Showing 49–72 of 320 trials